Her2 Antibodies - Trastuzumab Biosimilars and Biobetters/Biosuperiors

Reportstack has announced a new market research publication on Her2 Antibodies - Trastuzumab Biosimilars and Biobetters/Biosuperiors which provides a competitor evaluation in the field of recombinant antibodies targeting Her2 for treatment of Her2 positive breast and gastric cancer as of February 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

With the approval and launch of next generation Her2 antibodies Perjeta and Kadcyla, Roche has succeeded in boosting its Her2 franchise lead by Herceptin in 2013 to US$ 7.5 bln (+14% vs previous year).

The commercial attractiveness of trastuzumab has stimulated many companies to create and develop next generation anti-Her2 monoclonal antibodies (mabs) with improved properties compared with the humanized antibody trastuzumab. These biosuperior antibodies include antibody-drug conjugates, bi- and multispecific antibodies and engineered Her2 antibodies. The forthcoming patent expiry for Herceptin has boosted interest in and activties for developing biosimilar copies with the most advanced projects already approved and launched in less regulated markets.

The report includes a compilation of currently active projects in development of Her2 targeting antibodies for treatment of Her2 positive breast and gastric cancer. In addition, the report lists company-specific R&D pipelines of Her2 antibodies. Competitor projects are listed in a tabular format providing information on:

Drug Codes,
Target / Mechanism of Action,
Class of Compound,
Product Category,
R&D Stage and
additional comments with a hyperlink leading to the source of information.

To view the table of contents and know more details please visit Her2 Antibodies - Trastuzumab Biosimilars and Biobetters/Biosuperiors report.